Clinical Trials Logo

Hypersensitivity clinical trials

View clinical trials related to Hypersensitivity.

Filter by:

NCT ID: NCT06166745 Completed - Clinical trials for Dentinal Hypersensitivity

Efficacy of Sensi-IP Toothpaste in the Treatment of Dentinal Hypersensitivity Compared to a Sodium Fluoride Toothpaste

Start date: November 6, 2023
Phase: N/A
Study type: Interventional

The study is designed as a prospective, randomized, parallel arm, double blinded, pilot clinical trial.The primary objective is to evaluate the efficacy of Sensi-IP +NaF as compared to a NaF toothpaste in the reduction of dentin hypersensitivity in adult participants over 14 days. Study endpoints include Evaporative Air blast Stimuli (Schiff Airblast Sensitivity Score), Tactile Stimuli (Yeaple probe Assessment), Visual Analogue Scale Evaporative Stimuli and the occurrence of adverse events. The study will include 2 study arms: 1. Sodium fluoride toothpaste with Sensi IP (N=23) and 2. Sodium fluoride toothpaste (N=23). Total of 46 participants (ages 18-80 years) with at least one hypersensitive tooth in 2 different quadrants which are anterior to the molars will be enrolled.

NCT ID: NCT06165757 Completed - Pain Clinical Trials

The Effects of Non Harmonic and White Noise on Human Pain Sensitivity: a Study of Healthy Volunteers

Start date: October 10, 2023
Phase: N/A
Study type: Interventional

Study the effects of 60dB and 80dB white noise, 50-70dB and 70-90dB non harmonic tones on the basic pain threshold of subjects, including the threshold and tolerance of electrical stimulation pain,the threshold and tolerance of cold pain stimulation, and the threshold and tolerance of tenderness stimulation.

NCT ID: NCT06165458 Completed - Color Clinical Trials

Whitening Efficacy and Tooth Sensitivity of Different Concentrations of Hydrogen Peroxide Photoactivated With Violet or Blue LEDs

Start date: January 12, 2021
Phase: N/A
Study type: Interventional

This is a randomized, controlled, double-blind and repeated-measures clinical trial evaluated the photoactivation of hydrogen peroxide gels in different concentrations with blue or violet LED in terms of whitening efficacy and tooth sensitivity.

NCT ID: NCT06139120 Completed - Clinical trials for Central Sensitisation

The Segmental Distribution of Hypersensitivity in Patients With Chronic Subacromial Pain Syndrome

Start date: September 20, 2022
Phase:
Study type: Observational [Patient Registry]

This study aimed to determine the distribution of pain sensitivity according to body segments in patients with central sensitization associated with chronic subacromial pain syndrome (SPS).This cross-sectional study included patients with chronic SPS and central sensitization (patient group) and the same number of healthy participants as controls. The presence of central sensitization was determined using the Central Sensitization Inventory. To determine the segmental distribution of pain sensitivity, pressure pain threshold measurements were performed bilaterally from the shoulder, forearm, and leg.

NCT ID: NCT06113874 Completed - Clinical trials for Dentin Hypersensitivity

The Influence of Desensitizing Agent on Postoperative Sensitivity in Posterior Composite Restoration

Start date: July 5, 2022
Phase: N/A
Study type: Interventional

This study aims to investigate the influence of desensitizing agents on reducing post-operative sensitivity in posterior composite.

NCT ID: NCT06103656 Completed - Food Allergy Clinical Trials

E-B-FAHF-2, Multi OIT and Xolair for Food Allergy

FAHF-2
Start date: August 20, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is testing the use of Enhanced-Butanol purified-Food Allergy Herbal Formula-2 (E-B-FAHF-2) Chinese herbal therapy in combination with multi-food oral immunotherapy (OIT) and Xolair® (Omalizumab) to help children and adults who are allergic to foods be able to safely tolerate food allergens. Specifically in this protocol, the food allergens are milk, egg, peanut, almond, cashew, hazelnut, walnut, sesame, and/or wheat. Omalizumab is considered an investigational drug for the treatment of food allergies in children and adults. Investigational means it has not been approved by the Food and Drug Administration (FDA) for use in the U.S. The researchers hope to learn whether the addition of Chinese herbal therapy (E-B-FAHF-2) can improve the outcome of sustained unresponsiveness (which is the ability to consume a food allergen and pass an oral food challenge after being off treatment for 3 months) as compared to placebo (i.e. subjects with OIT/Omalizumab + herbal vs. OIT/Omalizumab + placebo), and will help adults and children be able to safely ingest the foods they are allergic to.

NCT ID: NCT06092567 Completed - Sensitivity, Tooth Clinical Trials

Post-operative Sensitivity in Composite Restorations

Start date: December 20, 2022
Phase: N/A
Study type: Interventional

Participants will be divided into groups. In group A, Composite restoration done using oblique incremental technique. In group B, Bulk-fill technique was used. VAS scoring to evaluate the primary outcome at one day, one week and two weeks.

NCT ID: NCT06072196 Completed - Prostatic Neoplasms Clinical Trials

A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Start date: October 4, 2023
Phase:
Study type: Observational

The purpose of this study is to learn about how long novel hormonal therapies are taken by men to treat mCSPC. Novel hormonal therapies in this study include study medicines abiraterone, apalutamide, and enzalutamide. Prostate cancer is one of the most common cancers in men. The prostate is a gland in the male body that helps make semen. Metastatic cancer is a cancer that has spread to other parts of the body. Castration-sensitive prostate cancer means the cancer is being controlled by keeping the testosterone levels as low as would be expected if the testicles were removed by surgery. This is a real-world study, not a clinical trial. This means that researchers will look at what happens when men receive the treatments prescribed by their own doctor as part of their usual healthcare treatment. In this study, researchers will use insurance claim information from Medicare claims data. The study will include patients' information from the database for men who: - Were identified to have mCSPC. - Started treatment with novel hormonal therapy (index date) for mCSPC. - Were 65 years of age or older one year before index date. Men in this study will be taking novel hormonal therapy for treatment of their mCSPC. We will describe how long men take novel hormonal therapy. This study will use patient information from insurance claims. It will take information one year before start of novel hormonal treatment until the end of insurance period or until information is available.

NCT ID: NCT06059417 Completed - Clinical trials for Dermatologic Conditions

Foam Tape Allergy a Sticky Situation

Start date: August 1, 2021
Phase: N/A
Study type: Interventional

Foam tape is commonly used in the emergency department as a dressing over chest tubes owing to its occlusive and compressible properties. There is a paucity of data regarding the incidence of significant cutaneous reactions to this material. We conducted a prospective trial to evaluate the incidence of dermatitis following application of foam tape to the upper arm of a cohort of healthy volunteers.

NCT ID: NCT06045026 Completed - Dentin Sensitivity Clinical Trials

A Real-World Evidence Study Evaluating Oral Health Related Quality Of Life With Use Of A Stannous Fluoride Anti-Sensitivity Toothpaste For Dentin Hypersensitivity Management

Start date: September 21, 2023
Phase: N/A
Study type: Interventional

This study will evaluate the impact of long-term use of a desensitizing toothpaste containing 0.454 percent (%) stannous fluoride (SnF2) on oral health related quality of life (OHrQoL) in a population of self-reported dentin hypersensitivity (DH) sufferers. Data generated will provide real world information on the DH experience and DH management with a daily use anti-sensitivity treatment.